AP2369A - Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. - Google Patents

Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Info

Publication number: AP2369A
Authority: AP; ARIPO
Prior art keywords: pyrrolopyrazoles; carbonylamino; kinase inhibitors; potent kinase; potent
Prior art date: 2005-12-21

Application number

AP2008004506A

Other languages

English (en)

Other versions

AP2008004506A0 (en

Inventor

Liming Dong

Chuangxing Guo

Yufeng Hong

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-21

Filing date

2006-12-12

Publication date

2012-02-29

2006-12-12 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-06-30 Publication of AP2008004506A0 publication Critical patent/AP2008004506A0/xx

2012-02-29 Application granted granted Critical

2012-02-29 Publication of AP2369A publication Critical patent/AP2369A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AP2008004506A 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. AP2369A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US75334905P	2005-12-21	2005-12-21
US86493206P	2006-11-08	2006-11-08
PCT/IB2006/003646 WO2007072153A2 (en)	2005-12-21	2006-12-12	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (2)

Publication Number	Publication Date
AP2008004506A0 AP2008004506A0 (en)	2008-06-30
AP2369A true AP2369A (en)	2012-02-29

Family

ID=38189022

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2008004506A AP2369A (en)	2005-12-21	2006-12-12	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Country Status (26)

Country	Link
US (1)	US7884117B2 (xx)
EP (1)	EP1979356B1 (xx)
JP (1)	JP4635089B2 (xx)
KR (1)	KR101029167B1 (xx)
AP (1)	AP2369A (xx)
AU (1)	AU2006327866B2 (xx)
BR (1)	BRPI0620354A2 (xx)
CA (1)	CA2634381C (xx)
CR (1)	CR10094A (xx)
CU (1)	CU23751B7 (xx)
DK (1)	DK1979356T3 (xx)
EA (1)	EA015513B1 (xx)
EC (1)	ECSP088558A (xx)
ES (1)	ES2435405T3 (xx)
GE (1)	GEP20104974B (xx)
HR (1)	HRP20130976T1 (xx)
IL (1)	IL191776A (xx)
MA (1)	MA30076B1 (xx)
ME (1)	ME00006B (xx)
MY (1)	MY151455A (xx)
NO (1)	NO20082482L (xx)
NZ (1)	NZ568692A (xx)
PL (1)	PL1979356T3 (xx)
PT (1)	PT1979356E (xx)
RS (2)	RS20080281A (xx)
WO (1)	WO2007072153A2 (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL385265A1 (pl) *	2008-05-23	2009-12-07	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
KR101881596B1 (ko)	2008-12-02	2018-07-24	웨이브 라이프 사이언시스 재팬 인코포레이티드	인 원자 변형된 핵산의 합성 방법
BR112012000828A8 (pt)	2009-07-06	2017-10-10	Ontorii Inc	Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
EP2937345B1 (en)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
WO2012039448A1 (ja) *	2010-09-24	2012-03-29	株式会社キラルジェン	不斉補助基
RU2013126036A (ru)	2010-11-17	2014-12-27	Ф. Хоффманн-Ля Рош Аг	Способ лечения опухолей
US8771682B2 (en)	2011-04-26	2014-07-08	Technische Universtität Dresden	Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
BR112014001244A2 (pt)	2011-07-19	2017-02-21	Wave Life Sciences Pte Ltd	métodos para a síntese de ácidos nucléicos funcionalizados
EP3569598A1 (en)	2011-11-17	2019-11-20	Dana Farber Cancer Institute, Inc.	Inhibitors of c-jun-n-terminal kinase (jnk)
CN104168898A (zh)	2012-03-16	2014-11-26	霍夫曼-拉罗奇有限公司	以pak1抑制剂治疗黑色素瘤的方法
BR112015000723A2 (pt)	2012-07-13	2017-06-27	Shin Nippon Biomedical Laboratories Ltd	adjuvante de ácido nucléico quiral
BR112015000784A8 (pt)	2012-07-13	2018-04-03	Wave Life Sciences Japan	Grupo auxiliar assimétrico
RU2015104762A (ru)	2012-07-13	2018-08-31	Уэйв Лайф Сайенсес Лтд.	Хиральный контроль
EP2909194A1 (en)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
USRE48175E1 (en)	2012-10-19	2020-08-25	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
WO2015058140A1 (en)	2013-10-18	2015-04-23	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2676734T3 (es)	2013-10-18	2018-07-24	Syros Pharmaceuticals, Inc.	Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
WO2015108046A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015107425A2 (en)	2014-01-16	2015-07-23	Wave Life Sciences Pte. Ltd.	Chiral design
WO2015164614A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
WO2015164604A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
JP6690543B2 (ja)	2014-10-31	2020-04-28	宇部興産株式会社	置換ジヒドロピロロピラゾール化合物
AU2015371251B2 (en) *	2014-12-23	2020-06-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh)	2015-03-27	2021-08-03	达纳-法伯癌症研究所股份有限公司	细胞周期蛋白依赖性激酶的抑制剂
US10702527B2 (en)	2015-06-12	2020-07-07	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
EP3309163A4 (en)	2015-06-15	2019-01-09	UBE Industries, Ltd.	SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
CA2996978A1 (en)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
WO2017144546A1 (en)	2016-02-23	2017-08-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
JP7590185B2 (ja)	2018-06-25	2024-11-26	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
EP3885347B1 (en)	2018-11-14	2023-11-22	UBE Corporation	Dihydropyrrolopyrazole derivative
AU2019413694B2 (en) *	2018-12-28	2025-03-20	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2020212484A1 (en)	2019-04-17	2020-10-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
EP4073102A4 (en)	2019-12-12	2024-05-08	Ting Therapeutics LLC	Compositions and methods for the prevention and treatment of hearing loss
WO2021198511A1 (en)	2020-04-03	2021-10-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en)	2020-07-08	2022-01-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of infectious diseases
WO2024261302A1 (en)	2023-06-22	2024-12-26	Institut National de la Santé et de la Recherche Médicale	Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en)	2023-10-09	2025-04-17	Institut National de la Santé et de la Recherche Médicale	Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002012242A2 (en) *	2000-08-10	2002-02-14	Pharmacia Italia S.P.A.	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) *	2002-12-19	2004-07-08	Pharmacia Italia Spa	Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) *	2003-09-23	2005-04-07	Vertex Pharmaceuticals Incorporated	Pyrazolopyrrole derivatives as protein kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060135508A1 (en)	2002-07-25	2006-06-22	Manuela Villa	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0229526D0 (en)	2002-12-19	2003-01-22	Astrazeneca Ab	Chemical compounds
WO2006072831A1 (en) *	2005-01-10	2006-07-13	Pfizer Inc.	Pyrrolopyrazoles, potent kinase inhibitors

2006
- 2006-12-12 DK DK06831731.2T patent/DK1979356T3/da active
- 2006-12-12 MY MYPI20082267 patent/MY151455A/en unknown
- 2006-12-12 ES ES06831731T patent/ES2435405T3/es active Active
- 2006-12-12 RS RSP-2008/0281A patent/RS20080281A/sr unknown
- 2006-12-12 PL PL06831731T patent/PL1979356T3/pl unknown
- 2006-12-12 RS RS20130498A patent/RS53029B/sr unknown
- 2006-12-12 CA CA2634381A patent/CA2634381C/en not_active Expired - Fee Related
- 2006-12-12 WO PCT/IB2006/003646 patent/WO2007072153A2/en not_active Ceased
- 2006-12-12 BR BRPI0620354-0A patent/BRPI0620354A2/pt not_active IP Right Cessation
- 2006-12-12 AU AU2006327866A patent/AU2006327866B2/en not_active Ceased
- 2006-12-12 HR HRP20130976TT patent/HRP20130976T1/hr unknown
- 2006-12-12 ME MEP-2008-8A patent/ME00006B/me unknown
- 2006-12-12 NZ NZ568692A patent/NZ568692A/en not_active IP Right Cessation
- 2006-12-12 US US12/158,241 patent/US7884117B2/en not_active Expired - Fee Related
- 2006-12-12 EA EA200801291A patent/EA015513B1/ru not_active IP Right Cessation
- 2006-12-12 EP EP06831731.2A patent/EP1979356B1/en active Active
- 2006-12-12 KR KR1020087014963A patent/KR101029167B1/ko not_active Expired - Fee Related
- 2006-12-12 JP JP2008546667A patent/JP4635089B2/ja not_active Expired - Fee Related
- 2006-12-12 PT PT68317312T patent/PT1979356E/pt unknown
- 2006-12-12 AP AP2008004506A patent/AP2369A/xx active
- 2006-12-12 GE GEAP200610777A patent/GEP20104974B/en unknown
2008
- 2008-05-27 IL IL191776A patent/IL191776A/en not_active IP Right Cessation
- 2008-06-02 NO NO20082482A patent/NO20082482L/no not_active Application Discontinuation
- 2008-06-18 EC EC2008008558A patent/ECSP088558A/es unknown
- 2008-06-19 CU CU20080115A patent/CU23751B7/es active IP Right Grant
- 2008-06-20 CR CR10094A patent/CR10094A/es unknown
- 2008-06-20 MA MA31060A patent/MA30076B1/fr unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002012242A2 (en) *	2000-08-10	2002-02-14	Pharmacia Italia S.P.A.	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) *	2002-12-19	2004-07-08	Pharmacia Italia Spa	Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) *	2003-09-23	2005-04-07	Vertex Pharmaceuticals Incorporated	Pyrazolopyrrole derivatives as protein kinase inhibitors

Also Published As

Publication number	Publication date
CU23751B7 (es)	2012-01-31
MA30076B1 (fr)	2008-12-01
IL191776A0 (en)	2008-12-29
US7884117B2 (en)	2011-02-08
BRPI0620354A2 (pt)	2011-11-08
RS20080281A (sr)	2009-09-08
CU20080115A7 (es)	2010-08-30
CR10094A (es)	2008-08-01
EP1979356A2 (en)	2008-10-15
AU2006327866A1 (en)	2007-06-28
CA2634381A1 (en)	2007-06-28
AP2008004506A0 (en)	2008-06-30
PT1979356E (pt)	2013-11-21
HRP20130976T1 (hr)	2013-11-22
ES2435405T3 (es)	2013-12-19
JP4635089B2 (ja)	2011-02-16
EA200801291A1 (ru)	2008-12-30
EP1979356B1 (en)	2013-09-18
US20090318440A1 (en)	2009-12-24
HK1128290A1 (en)	2009-10-23
WO2007072153A3 (en)	2007-10-25
WO2007072153A2 (en)	2007-06-28
AU2006327866B2 (en)	2012-06-14
WO2007072153A8 (en)	2008-08-14
DK1979356T3 (da)	2013-11-18
NZ568692A (en)	2011-07-29
KR20080080567A (ko)	2008-09-04
IL191776A (en)	2013-03-24
RS53029B (sr)	2014-04-30
ECSP088558A (es)	2008-07-30
JP2009520805A (ja)	2009-05-28
GEP20104974B (en)	2010-04-26
PL1979356T3 (pl)	2014-01-31
MY151455A (en)	2014-05-30
CA2634381C (en)	2011-03-08
EA015513B1 (ru)	2011-08-30
NO20082482L (no)	2008-07-02
MEP0808A (xx)	2010-02-10
KR101029167B1 (ko)	2011-04-12
ME00006B (me)	2010-02-10

Publication	Publication Date	Title
AP2369A (en)	2012-02-29	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.
IL184275A0 (en)	2007-10-31	Pyrrolopyrazoles, potent kinase inhibitors
EG25264A (en)	2011-11-30	Biphenyl-n-(4-pyridyl) methylsulfonamides.
AP2402A (en)	2012-04-30	Amine derivatives.
IL190078A0 (en)	2008-08-07	Kinase inhibitors
EG25271A (en)	2011-12-04	Fungicidal combinations.
GB2424882B (en)	2008-08-06	Selective kinase inhibitors
SI2270008T1 (sl)	2013-01-31	8-heteroaril-3-alkil-1,3-dihidro-imidazo(4,5-c)kinolin-2-oni kot inhibitorji PI-3 kinaz
IL192033A0 (en)	2008-12-29	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AP2006003659A0 (en)	2006-06-30	Azabenzofuran substituted thioureas, inhibitors ofviral replication
AP2281A (en)	2011-10-31	Novel compounds.
SI1943243T1 (sl)	2011-04-29	Inhibotorji kinaz
ZA200805028B (en)	2009-12-30	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
AP2337A (en)	2011-12-14	Motilide compounds.
AP2006003791A0 (en)	2006-10-31	1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
ZA200804667B (en)	2010-05-26	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NL1031384A1 (nl)	2006-09-20	Gesubstitueerde aryl-1,4-pyrazinederivaten.
GB0505823D0 (en)	2005-04-27	Boardmate, boardmate adjustable
GB0504761D0 (en)	2005-04-13	Alfatie, Coliawel, Omaatie
ITRM20050033U1 (it)	2006-09-16	Semicabina per fumatori.
ITTO20050072U1 (it)	2006-12-01	Armadio-espositore, particolarmente per tabaccherie
IL189985A0 (en)	2008-08-07	Kinase inhibitors
ZA200803287B (en)	2009-10-28	Kinase inhibitors
CY2449B1 (en)	2005-06-03	Multiple srengthened carton.
PL378279A1 (pl)	2007-06-11	Układ do osuszania gazów zwłaszcza dla komór klimatycznych